


PHARMACEUTICAL 2022

Minerva Neurosciences Inc. Rank 345 of 475









PHARMACEUTICAL 2022



Minerva Neurosciences Inc. Rank 345 of 475

The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is -265%, being 11% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	62,201
Cost of Goods Sold	0
Intangible Assets	14,869
Liabilities, Current	2,819
Liabilities, Non-Current	0
Other Assets	51
Other Compr. Net Income	0
Other Expenses	4,524
Other Liabilities	66,327
Other Net Income	-16
Property and Equipment	0
Research and Development	32,039
Revenues	0
Selling, General and Administrative Expense	13,327

Output Variable	Value in 1000 USD
Assets	77,122
Liabilities	69,146
Expenses	49,890
Stockholders Equity	7,976
Net Income	-49,906
Comprehensive Net Income	-49,906
Economic Capital Ratio	-265%

